Last reviewed · How we verify
Uric Acid Nephropathy Gout — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Aloprim | ALLOPURINOL | Casper Pharma Llc | Xanthine Oxidase Inhibitor [EPC] | Xanthine dehydrogenase/oxidase | 1966-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
- — Aloprim · FDA · approved · US
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Casper Pharma Llc · 1 drug in Uric Acid Nephropathy Gout
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Uric Acid Nephropathy Gout:
- Uric Acid Nephropathy Gout treatment updates — RSS
- Uric Acid Nephropathy Gout treatment updates — Atom
- Uric Acid Nephropathy Gout treatment updates — JSON
Cite this brief
Drug Landscape (2026). Uric Acid Nephropathy Gout — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/uric-acid-nephropathy-gout. Accessed 2026-06-10.
Related
- Uric Acid Nephropathy Gout full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing